HSBC Knock-Out CHKP/ DE000HG97QY9 /
| 2024-05-30 8:19:20 AM | Chg.-0.08 | Bid10:35:57 AM | Ask10:35:57 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.96EUR | -3.92% | 1.99 Bid Size: 10,000 |
2.11 Ask Size: 10,000 |
Check Point Software... | 127.893 USD | 2078-12-31 | Call |
GlobeNewswire
05-29
DEADLINE ALERT for LUNA, HRT, and CKPT: The Law Offices of Frank R. Cruz Reminds Investors of Class ...
GlobeNewswire
05-29
DEADLINE ALERT for HRT, CKPT, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class ...
GlobeNewswire
05-29
UPDATE -- Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of L...
GlobeNewswire
05-29
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
GlobeNewswire
05-29
Georgiamune Expands Cancer Treatment Pipeline with Two Novel Drugs Within Five Months of Launch
GlobeNewswire
05-29
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology...
GlobeNewswire
05-29
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KI...
GlobeNewswire
05-29
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR ...
GlobeNewswire
05-28
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual ...
GlobeNewswire
05-28
7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with...
GlobeNewswire
05-28
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkp...
GlobeNewswire
05-28
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Tril...
GlobeNewswire
05-28
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
GlobeNewswire
05-27
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel...
GlobeNewswire
05-27
CKPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Checkpoint Therapeutics, Inc. ...
GlobeNewswire
05-24
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenaden...
GlobeNewswire
05-23
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire
05-23
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
GlobeNewswire
05-23
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at A...
GlobeNewswire
05-23
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Adva...
GlobeNewswire
05-23
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study i...
GlobeNewswire
05-23
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combinatio...
